eligibility for glp 1 If you're covered by the State Health Benefit Plan (SHBP) and take a weight-loss GLP-1 medication (like Wegovy or Zepbound), a change is coming. Starting February 1, 2026, SHBP will require these qualifications for glp-1 meds GLP-1
Description
Phase 2 Trial Design Participants: 338 adults with obesity (BMI 30) or overweight with comorbidities (BMI 27), without diabetes Duration: 48 weeks Dosing groups: Placebo, 1mg, 4mg, 8mg, or 12mg weekly (with gradual dose escalation over 20-24 weeks) Primary endpoint: Percentage change in body weight from baseline Beyond Weight Loss: Metabolic Improvements Beyond weight loss, the 12mg dose also improved several cardiometabolic markers: Blood pressure: Systolic BP decreased by 7.4 mmHg (clinically significant reduction) Lipids: Triglycerides fell 30%, HDL cholesterol increased 8% Glucose control: HbA1c decreased 0.4% even in participants without diabetes Liver health: Markers of fatty liver disease (ALT, AST) improved significantly Inflammation: C-reactive protein (CRP) decreased, indicating reduced systemic inflammation What this means: Retatrutide appears to improve the metabolic dysfunction behind obesity-related diseases, not just the weight itself

Finding #2: More Noom app use = over 25% more weight loss at 40 weeks Rigorous studies have shown that higher levels of engagement in the Noom app drive higher weight loss, but what about for members on GLP-1 medication
If you are approved, you select the medication you want, and it gets shipped directly to your home

How Bupropion Works for Weight Loss Bupropion is commonly used to increase weight loss
Taking metformin with food and spacing it from other medications can further reduce stomach upset

Glucagon responses of isolated cells to glucose, insulin, somatostatin, and leptin